Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer
- 1 May 1995
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 71 (5), 1061-1064
- https://doi.org/10.1038/bjc.1995.204
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradationClinical Chemistry, 1993
- Disodium Pamidronate Identifies Differential Osteoclastic Bone Resorption in Metastatic Prostate CancerBritish Journal of Urology, 1992
- Radioimmunoassay of the carboxyterminal propeptide of human type I procollagenClinical Chemistry, 1990
- Clodronate Therapy of Metastatic Bone Disease in Patients with Prostatic CarcinomaPublished by Springer Science and Business Media LLC ,1989
- Serum Osteocalcin Concentration in Patients with Prostatic CancerAmerican Journal of Clinical Oncology, 1988
- Generalised Increase in Bone Resorption in Carcinoma of the ProstateBritish Journal of Urology, 1985
- Spread of prostatic cancer to boneUrology, 1983
- Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalaciaCancer, 1983
- Prostatic CarcinomaNew England Journal of Medicine, 1979
- Mechanisms of bone destruction in the development of skeletal metastasesNature, 1976